BMS-986249 + nivolumab

BMS-986249 + nivolumab is a combination of an engineered probody (BMS-986249) and a monoclonal antibody checkpoint inhibitor (nivolumab) for the treatment of advanced solid tumors, including metastatic melanoma. BMS-986249 is a peptide-masked version of ipilimumab (Yervoy) that targets CTLA-4 but only becomes active in the tumor microenvironment by protease-mediated cleavage, aiming to reduce systemic toxicity while retaining anti-tumor efficacy. Nivolumab (Opdivo) is a monoclonal antibody that targets the programmed death-1 (PD-1) receptor, preventing cancer cells from evading immune detection. Together, these two immune checkpoint inhibitors are designed to enhance T cell activation and anti-tumor immune responses while minimizing systemic side effects. The combination is being developed by Bristol Myers Squibb and CytomX Therapeutics and is in advanced clinical trials for metastatic melanoma and other cancers[1][2][3][4][5][6][7].

Other names

anti-CTLA-4 probody + anti–PD-1